Surgery is the preferred treatment for bile duct hamartomas

Yang, Xiaoyu; Zhang, Haibo; Wu, Bin; Li, Aijun; Fu, Xiaohui

doi:10.3892/mco.2017.1354

Cited by 11 publications

(9 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, there were a few cases when CA 19-9, AFP, and CEA levels were increased. This is unlikely to be unique to biliary hamartomas, as increased tumor markers are linked to a variety of cancers and may also be present in situations with underlying liver cirrhosis, portal hypertension, and jaundice [ 86 ]. As a result, the significance of tumor markers in biliary duct hamartomas remains debatable.…”

Section: Reviewmentioning

confidence: 99%

Biliary Duct Hamartomas: A Systematic Review

Sheikh¹,

Nguyen²,

Leyba³

et al. 2022

Cureus

View full text Add to dashboard Cite

Biliary duct hamartomas are benign intrahepatic bile duct lesions. Despite being primarily incidental findings on imaging, these lesions can provide a diagnostic conundrum due to their shared characteristics with malignant tumors. The goal of this systematic review is to offer a thorough clinical profile of biliary duct hamartomas. There were 139 cases of biliary duct hamartomas identified in a structured systematic review of the literature. Patient demographics, clinical presentation, significant laboratory and imaging data, diagnostic modalities, treatment choices, and outcomes were all studied and reported. Biliary duct hamartomas present with mild symptoms and laboratory abnormalities, and while being visible on imaging, the results are non-specific and may require biopsy in case of red flag signs such as weight loss and a progressive increase in the size of the lesion. Furthermore, there are currently no published guidelines for the treatment of biliary duct hamartomas, and many people have had surgery despite the clinically benign nature of these abnormalities. As per the findings of the study, individuals who exhibit signs of malignancy should be investigated further. Eyeballing for red flag symptoms, followed by a specialized imaging scan and invasive treatment, is the three-step approach to biliary duct hamartomas. Since our recommendations include a shift in strategy and do not contradict existing rules, there are likely to be few roadblocks to improvement; the key barriers being technological equipment and image quality. In this study, we intended to pave the way for future research in the field. In our opinion, the next decade will bring a better understanding of the characteristics of biliary hamartomas, disease symptoms, and better recognition of any suspicious features. These indications will aid in reducing the number of unneeded surgical or invasive operations. Finally, the findings of these future studies will allow the medical community to improve and provide the best care possible.

show abstract

Section: Reviewmentioning

confidence: 99%

Biliary Duct Hamartomas: A Systematic Review

Sheikh¹,

Nguyen²,

Leyba³

et al. 2022

Cureus

View full text Add to dashboard Cite

show abstract

“…Abnormal development of the portal tract, including the bile duct, is the primary cause of MHL. Moreover, progression from bile duct hamartoma to iCCA has been reported in previous studies [11,12]. Although the mechanism and histopathological association between MHL and bile duct hamartoma have not been uncovered since both hamartomas include bile duct structures, iCCA should be considered in the differential diagnosis when malignant transformation of MHL is suspected.…”

Section: Discussionmentioning

confidence: 82%

Progression of a persisting mesenchymal hamartoma to intrahepatic cholangiocarcinoma 24 years after the initial diagnosis: A case report

Gang

Choi

Lee

et al. 2022

Ann Hepatobiliary Pancreat Surg

View full text Add to dashboard Cite

Mesenchymal hamartoma of the liver (MHL) is a rare benign tumor that often presents in early childhood, and it rarely occurs in adulthood. Aberrant development of the portal tract is a known cause of MHL. Although limited information is available on the natural course of MHL, malignant transformation has been reported in a few cases. Here, we report a case of a 26-year-old female with intrahepatic cholangiocarcinoma secondary to unresected MHL. The patient underwent resection of the hepatic mass, which was diagnosed as MHL at 2 years of age, due to an increase in mass size and a suspicion of malignant transformation during work-up. Histopathology confirmed intrahepatic adenosquamous carcinoma in the background of MHL, with a T2N0M0 pathological stage (stage II). The surgical margin was free from tumor cells. The patient fully recovered postoperatively and started receiving adjuvant chemotherapy. Previous case reports have only reported about the development of undifferentiated embryonal sarcoma or angiosarcoma as malignant transformation of MHL. Cases of other malignancies have not been published; however, it is difficult to rule out the occurrence of various malignancies related to the portal tract when considering the pathogenesis of the disease. To the best of our knowledge, this is the first case report of adenocarcinoma of bile duct origin secondary to MHL. This case report suggests that aggressive surgical management should be considered after the initial diagnosis of MHL.

show abstract

“…This is most likely not specific to biliary hamartomas as elevated tumor markers are associated with many malignancies and might also be elevated in cases of underlying liver cirrhosis, portal hypertension, and jaundice. 85 Many common features were noted on ultrasonography. In most of the cases, the lesions were hypoechogenic (80%) and less than 1 cm in size (53.2%).…”

Section: Discussionmentioning

confidence: 99%

Biliary Duct Hamartomas: A Systematic Review

Shekhar

Javed

et al. 2021

Preprint

View full text Add to dashboard Cite

Biliary duct hamartomas are benign lesions of intrahepatic bile ducts. Oftentimes an incidental finding on imaging, these lesions can pose a diagnostic dilemma because of their overlapping features with malignant masses. We performed a structured systematic review of literature and identified 139 cases of biliary duct hamartomas. Patient demographics, clinical presentation with key laboratory and imaging findings, diagnostic modalities, management strategies, and outcomes were analyzed and systematically summarized. The systematic review is aimed to help with better understanding of biliary duct hamartomas and its principal features.

show abstract

Surgery is the preferred treatment for bile duct hamartomas

Cited by 11 publications

References 23 publications

Biliary Duct Hamartomas: A Systematic Review

Biliary Duct Hamartomas: A Systematic Review

Progression of a persisting mesenchymal hamartoma to intrahepatic cholangiocarcinoma 24 years after the initial diagnosis: A case report

Biliary Duct Hamartomas: A Systematic Review

Contact Info

Product

Resources

About